Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage

Jieun Koh; Min Jung Kim

doi:10.3348/kjr.2018.0231

Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage

Jieun Koh, Min Jung Kim

Department of Radiology

Research output: Contribution to journal › Editorial › peer-review

18 Citations (Scopus)

Abstract

In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.

Original language	English
Pages (from-to)	69-82
Number of pages	14
Journal	Korean journal of radiology
Volume	20
Issue number	1
DOIs	https://doi.org/10.3348/kjr.2018.0231
Publication status	Published - 2019 Jan

Bibliographical note

Funding Information:
Received April 12, 2018; accepted after revision July 9, 2018. This study was supported by the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (grant 2017R1A2B4010407). Corresponding author: Min Jung Kim, MD, PhD, Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. • Tel: (822) 2228-7400 • Fax: (822) 393-3035 • E-mail: mines@yuhs.ac This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Funding Information:
This study was supported by the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (grant 2017R1A2B4010407).

Publisher Copyright:
© 2019 The Korean Society of Radiology.

All Science Journal Classification (ASJC) codes

Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.3348/kjr.2018.0231

Fingerprint Dive into the research topics of 'Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage'. Together they form a unique fingerprint.

Cite this

@article{6dd30e5fb4d44f8dbc23c49c20adb4e8,

title = "Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage",

abstract = "In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.",

author = "Jieun Koh and Kim, {Min Jung}",

note = "Funding Information: Received April 12, 2018; accepted after revision July 9, 2018. This study was supported by the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (grant 2017R1A2B4010407). Corresponding author: Min Jung Kim, MD, PhD, Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. • Tel: (822) 2228-7400 • Fax: (822) 393-3035 • E-mail: mines@yuhs.ac This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Funding Information: This study was supported by the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (grant 2017R1A2B4010407). Publisher Copyright: {\textcopyright} 2019 The Korean Society of Radiology.",

year = "2019",

month = jan,

doi = "10.3348/kjr.2018.0231",

language = "English",

volume = "20",

pages = "69--82",

journal = "Korean Journal of Radiology",

issn = "1229-6929",

publisher = "Korean Radiological Society",

number = "1",

}

TY - JOUR

T1 - Introduction of a new staging system of breast cancer for radiologists

T2 - An emphasis on the prognostic stage

AU - Koh, Jieun

AU - Kim, Min Jung

N1 - Funding Information: Received April 12, 2018; accepted after revision July 9, 2018. This study was supported by the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (grant 2017R1A2B4010407). Corresponding author: Min Jung Kim, MD, PhD, Department of Radiology, Severance Hospital, Research Institute of Radiological Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. • Tel: (822) 2228-7400 • Fax: (822) 393-3035 • E-mail: mines@yuhs.ac This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Funding Information: This study was supported by the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning, Republic of Korea (grant 2017R1A2B4010407). Publisher Copyright: © 2019 The Korean Society of Radiology.

PY - 2019/1

Y1 - 2019/1

N2 - In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.

AB - In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.

UR - http://www.scopus.com/inward/record.url?scp=85059645475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059645475&partnerID=8YFLogxK

U2 - 10.3348/kjr.2018.0231

DO - 10.3348/kjr.2018.0231

M3 - Editorial

C2 - 30627023

AN - SCOPUS:85059645475

VL - 20

SP - 69

EP - 82

JO - Korean Journal of Radiology

JF - Korean Journal of Radiology

SN - 1229-6929

IS - 1

ER -

Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this